Open AccessContinuous infusion of apomorphine in a series of thirty patients with parkinson's disease
Author(s) -
Rezzak Yılmaz,
Çağlar Sarılar,
Cenk Akbostancı
Publication year - 2019
Publication title -
milli nevrologiya jurnalı
Language(s) - English
Resource type - Journals
eISSN - 2617-8966
pISSN - 2227-0892
DOI - 10.28942/nnj.v1i3.181
Subject(s) - apomorphine , deep brain stimulation , medicine , parkinson's disease , dopamine agonist , adverse effect , subthalamic nucleus , disease , anesthesia , motor symptoms , medical record , dopamine , surgery , dopaminergic
Apomorphine is a dopamine agonist primarily used for the treatment of motor fluctuations and severe dyskinesias in late – stage Parkinson’s Disease. We retrospectively studied medical records of 30 patients who were on continuous apomorphine infusion treatment. They were evaluated for their disease characteristics, satisfaction for the therapy and adverse events. Results showed that 17 patients were satisfied with the therapy. The main reason of cessation of therapy (15 patients) was subthalamic nucleus deep brain stimulation. Arrythmia and subcutaneous nodules were relatively rare (3 patients). Results were compared with similar studies. Apomorphine therapy appears as a safe option for patients with motor complications and cognitive or neuropsychiatric problems.